ERASErasca, Inc.

1. Aug 24, 2026On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.Other event · Form 8-K
2. Aug 11, 2026Erasca Reports Second Quarter 2026 Business Updates and Financial Results.Earnings release · press release
3. Aug 10, 2026Appointment of President, Research & Development Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. (“the Company”)Director or officer change · Form 8-K
4. Jul 14, 2026On July 13, 2026, Erasca, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) …Other event · Form 8-K
5. Jul 13, 2026On July 13, 2026, Erasca, Inc. (the “Company”) announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.Other event · Form 8-K
6. May 11, 2026Erasca Reports First Quarter 2026 Business Updates and Financial Results.Earnings release · press release
7. Apr 27, 2026On April 27, 2026, Erasca, Inc. (the “Company”) announced positive preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.Other event · Form 8-K
8. Apr 27, 2026On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”)Regulation FD disclosure · Form 8-K
9. Apr 21, 2026On April 21, 2026, Erasca, Inc. (the “Company”) narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026.Other event · Form 8-K
10. Jan 29, 2026On January 20, 2026, Erasca, Inc. (the “Company”) disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.